CEO Anders Göransson invests in Bactiguard
Anders Göransson, Bactiguard's CEO, has acquired shares in Bactiguard Holding AB (publ) corresponding to an amount of SEK 3 million.
The investment comprises a total of 17 620 B shares at a share price of SEK 170,28 which corresponds to the average closing price of the stock exchange during the ten preceding trading days. The transaction was made with the two main shareholders Christian Kinch and Thomas von Koch as counterparties, and was completed after the stock exchange closed on 16 November.
”I am immensely delighted that Anders as the new CEO invests in the company. We encourage the leadership team to have a significant stake in the company to be able to take part in the value creation they contribute to”, says Chairman of the Board Thomas von Koch.
”We are in the middle of an exciting growth phase and, for me, it is natural to also invest in the company I lead. Our mission to save lives through infection prevention and to reduce the use of antibiotics is something I am passionate about”, says Anders Göransson CEO.
For further information, please contact:
Gabriella Björknert Caracciolo, CFO and deputy CEO, mobile: +46 72 141 62 49
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with the Bactiguard technology are market leading in the USA and Japan through our licensing partner BD, and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue friendly.
Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about Bactiguard www.bactiguard.com